Bicara Reports Substantial Enrollment in FORTIFI-HN01 Cancer Trial
Bicara expects topline results from an interim analysis in mid-2027 and says its $442.3 million in cash, cash equivalents and marketable securities can fund operations into the first half of 2029.
Discover more from Coin Gazette
Subscribe to get the latest posts sent to your email.